ClinicalTrials.gg
CompletedNCT02031471Updated Aug 1, 2017Results posted

TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

A Phase 3 interventional study of tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
75th of 110
57 · median 97
Started
2014
with 8 others
Phase 3
65 of 110
none open now
Registered
83rd of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 75th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 83rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying anti-rheumatic drug (DMARDs) in participants with active rheumatoid arthritis (RA) who are naïve to tocilizumab. Participants will receive tocilizumab 162 milligram (mg) subcutaneously weekly for 24 weeks. Participants who complete the core study achieving at least a moderate European League Against Rheumatism (EULAR) response at Week 24 may enter the extension phase and receive for a further 28 weeks at the most.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, >/= 18 years of age
  • Active moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria or EULAR/ACR (2010) criteria
  • Inadequate response or intolerant to previous therapy with two or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), one of which is methotrexate, administered in an optimal way during at least 3 months; eligible participants may also be inadequate responders to a maximum of one biologic DMARD
  • Oral (\</= 10 milligram per day (mg/day) prednisolone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the recommended dose) are permitted if on stable dose regimen for >/= 4 weeks prior to baseline
  • Permitted DMARDs are allowed if at stable dose for at least 4 weeks prior to baseline
  • Receiving treatment on an outpatient basis, not including tocilizumab
  • Females of and males with female partners of childbearing potential must agree to use reliable means of as defined by protocol

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline or during long term extension (LTE) period
  • Rheumatic disease other than rheumatoid arthritis
  • Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16
  • Prior history of or current inflammatory joint disease other than RA
  • Exposure to tocilizumab (intravenous or subcutaneous) at any time prior to baseline
  • Treatment with any agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
  • Intraarticular or parenteral within 4 weeks prior to baseline
  • History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
  • Evidence of serious concomitant disease or disorder
  • Known active current or history of recurrent infection
  • Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
  • Active Tuberculosis (TB) requiring treatment within the previous 3 years
  • Positive for or
  • Primary or secondary immunodeficiency (history of or currently active)
  • Pregnant or lactating women
  • Neuropathies or other conditions that might interfere with pain evaluation
  • Inadequate hematologic, renal or liver function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.

    Drug: tocilizumab

Interventions

  • Fixed dose of 162 mg subcutaneously weekly

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS)

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.

    Time frame: From baseline to Week 24

  2. Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS)

    The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores

    The ACR core set of outcome measures and their definition of improvement includes a \>= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a \>= 50% improvement in the same parameters and an ACR70 requires a \>= 70% improvement.

    Time frame: From Baseline to Week 2, Week 24, and Week 52

  2. Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria

    EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline \>1.2 with a DAS28 score of \<=3.2; moderate responders = decrease from baseline \>1.2 with a DAS28 score of \>3.2, or decrease from baseline \>0.6 to \<=1.2 with a DAS28 score of \<=5.1; non-responders = decrease from baseline \<=0.6 or decrease from baseline \>0.6 and \<=1.2 with a DAS28 score of \>5.1.

    Time frame: From Baseline to Week 2, Week 24

  3. Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)

    SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  4. Change in Total Tender/Swollen Joint Counts (TJC/SJC)

    An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  5. Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation

    Time frame: Up to Week 52

  6. Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity

    CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score \> 2.8 and ≤ 10.0; Moderate disease activity = score \> 10.0 and ≤ 22.0; High disease activity = score \> 22.0.

    Time frame: Baseline to Week 2, Week 24 and Week 52

  7. Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity

    SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score \> 3.3 and ≤ 11.0; Moderate disease activity = score \> 11.0 and ≤ 26.0; high disease activity = score \> 26.0.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  8. Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity

    The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. Clinical remission = score \<2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score \> 3.2 and ≤5.1; High disease activity = score \>5.1.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  9. Percentage of Participants Achieving a Clinically Significant Improvement in DAS28

    The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  10. Change From Baseline in Physician's Global Assessment of Disease Activity VAS

    Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100= "maximum disease activity". This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  11. Change From Baseline in Patient's Global Assessment of Disease Activity VAS

    PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100="maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  12. Change From Baseline in Patient's Assessment of Pain VAS

    Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no pain" and the extreme right end 100="unbearable pain". A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2 and Week 24

  13. Acute Phase Reactants: Change From Baseline in CRP

    A negative change from baseline in CRP level indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  14. Acute Phase Reactants: Change From Baseline in ESR

    A negative change from baseline in ESR indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  15. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

    The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  16. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

    The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  17. Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 4, Week 24 and Week 52

  18. Change From Baseline in Patient Quality of Sleep VAS

    The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no difficulty to sleep" and the extreme right end 100="extreme sleeping difficulties". A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  19. Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF)

    The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 4, Week 24 and Week 52

  20. Change From Baseline in Patient Fatigue VAS

    The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no fatigue" and the extreme right end 100="extreme fatigue". A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  21. Change From Baseline in Patient Satisfaction VAS

    The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no satisfaction" and the extreme right end 100="extremely satisfied". A positive change from baseline indicates an improvement.

    Time frame: From Baseline to Week 2, Week 24 and Week 52

  22. Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS)

    The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low \< 10, moderate 10-17 and high \> 17. A negative change from baseline indicates an improvement.

    Time frame: From Baseline to Week 24

  23. Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores

    The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction.

    Time frame: Week 24

  24. Safety: Percentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Up to 52 weeks

  25. Safety: Percentage of Participants With Anti-tocilizumab Antibodies

    Time frame: Baseline, Week 24

07

Results

Posted Jan 4, 2017

Participant flow

24 Week Treatment Period
Participant flow — 24 Week Treatment Period
MilestoneTocilizumab
Started57
Completed46
Not completed11
Withdrew: Adverse event6
Withdrew: Participant decision to withdraw2
Withdrew: Protocol violation1
Withdrew: Insufficient therapeutic response1
Withdrew: Hypersensitivity reaction1
Long Term Extension (LTE) Period
Participant flow — Long Term Extension (LTE) Period
MilestoneTocilizumab
Started39
Completed37
Not completed2
Withdrew: Adverse event1
Withdrew: Insufficient therapeutic response1

Outcome measures

PrimaryChange From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS)

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.

Time frame:
From baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS)
Units on a scaleTocilizumab
Baseline (n=56)5.55 ± 1.17
Change at Week 24 (n=42)-3.24 ± 1.47
PrimaryChange From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS)

The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.

Time frame:
From baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS)
Units on a scaleTocilizumab
Baseline (n= 27)5.73 ± 1.33
Change at Week 24 (n= 20)-3.21 ± 1.42
SecondaryPercentage of Participants With Positive American College of Rheumatology (ACR) Response Scores

The ACR core set of outcome measures and their definition of improvement includes a \>= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a \>= 50% improvement in the same parameters and an ACR70 requires a \>= 70% improvement.

Time frame:
From Baseline to Week 2, Week 24, and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores
percentage of participantsTocilizumab
Baseline: ACR 20 (n=55)0
Week 2: ACR 20 (n=51)21.6
Week 24: ACR 20 (n=39)84.6
Week 52: ACR 20 (n=8)100
Baseline: ACR 50 (n=55)0
Week 2: ACR 50 (n=52)1.9
Week 24: ACR 50 (n=39)66.7
Week 52: ACR 50 (n=8)62.5
Baseline: ACR 70 (n=55)0
Week 2: ACR 70 (n=52)0
Week 24: ACR 70 (n=39)38.5
Week 52: ACR 70 (n=8)25.0
SecondaryPercentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria

EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline \>1.2 with a DAS28 score of \<=3.2; moderate responders = decrease from baseline \>1.2 with a DAS28 score of \>3.2, or decrease from baseline \>0.6 to \<=1.2 with a DAS28 score of \<=5.1; non-responders = decrease from baseline \<=0.6 or decrease from baseline \>0.6 and \<=1.2 with a DAS28 score of \>5.1.

Time frame:
From Baseline to Week 2, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria
percentage of participantsTocilizumab
Week 2: Good response (n=56)17.9
Week 24: Good response (n=42)76.2
Week 2: Moderate response (n=56)50.0
Week 24: Moderate response (n=42)19.0
Week 2: No response (n=56)32.1
Week 24: No response (n=42)4.8
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)

SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)
Units on a scaleTocilizumab
Baseline (n=53)33.26 ± 13.50
Change at Week 2: SDAI (n=52)-9.00 ± 11.89
Change at Week 24: SDAI (n=38)-25.33 ± 13.63
Change at Week 52: SDAI (n=7)-34.04 ± 16.01
Baseline: CDAI (n= 55)31.86 ± 12.60
Change at Week 2: CDAI (n=55)-7.61 ± 11.51
Change at Week 24: CDAI (n=42)-23.55 ± 13.03
Change at Week 52: CDAI (n=8)-29.99 ± 13.89
SecondaryChange in Total Tender/Swollen Joint Counts (TJC/SJC)

An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Joint Counts
Change in Total Tender/Swollen Joint Counts (TJC/SJC)
Joint CountsTocilizumab
Baseline: TJC (n=53)16.02 ± 11.77
Change at Week 2: TJC (n=53)-3.58 ± 8.91
Change at Week 24: TJC (n=41)-12.10 ± 11.07
Change at Week 52: TJC (n=8)-17.25 ± 13.02
Baseline: SJC (n=55)10.20 ± 7.14
Change at Week 2: SJC (n=55)-3.93 ± 7.33
Change at Week 24: SJC (n=42)-9.81 ± 7.84
Change at Week 52: SJC (n=8)-11.75 ± 7.76
SecondaryPercentage of Participants With Corticosteroid Dose Reduction/Discontinuation
Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation
percentage of participantsTocilizumab
Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation50.0
SecondaryPercentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity

CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score \> 2.8 and ≤ 10.0; Moderate disease activity = score \> 10.0 and ≤ 22.0; High disease activity = score \> 22.0.

Time frame:
Baseline to Week 2, Week 24 and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity
percentage of participantsTocilizumab
Baseline: Clinical remission (n=55)0
Week 2: Clinical remission (n=56)1.8
Week 24: Clinical remission (n=43)30.2
Week 52: Clinical remission (n=8)37.5
Baseline: Low disease activity (n=55)0
Week 2: Low disease activity (n=56)7.1
Week 24: Low disease activity (n=43)34.9
Week 52: Low disease activity (n=8)25.0
Baseline: Moderate disease activity (n=55)21.8
Week 2: Moderate disease activity (n=56)48.2
Week 24: Moderate disease activity (n=43)30.2
Week 52: Moderate disease activity (n=8)37.5
Baseline: High disease activity (n=55)78.2
Week 2: High disease activity (n=56)42.9
Week 24: High disease activity (n=43)4.7
Week 52: High disease activity (n=8)0
SecondaryPercentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity

SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score \> 3.3 and ≤ 11.0; Moderate disease activity = score \> 11.0 and ≤ 26.0; high disease activity = score \> 26.0.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity
percentage of participantsTocilizumab
Baseline: Clinical remission (n=53)0
Week 2: Clinical remission (n=55)1.8
Week 24: Clinical remission (n=40)30.0
Week 52: Clinical remission (n=7)42.9
Baseline: Low disease activity (n=53)0
Week 2: Low disease activity (n=55)7.3
Week 24: Low disease activity (n=40)40.0
Week 52: Low disease activity (n=7)14.3
Baseline: Moderate disease activity (n=53)30.2
Week 2: Moderate disease activity (n=55)54.5
Week 24: Moderate disease activity (n=40)25.0
Week 52: Moderate disease activity (n=7)42.9
Baseline: High disease activity (n=53)69.8
Week 2: High disease activity (n=55)36.4
Week 24: High disease activity (n=40)5.0
Week 52: High disease activity (n=7)0
SecondaryPercentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity

The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. Clinical remission = score \<2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score \> 3.2 and ≤5.1; High disease activity = score \>5.1.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity
percentage of participantsTocilizumab
Baseline: Clinical remission (n=56)0
Week 2: Clinical remission (n=56)7.1
Week 24: Clinical remission (n=42)64.3
Week 52: Clinical remission (n=8)87.5
Baseline: Low disease activity (n=56)1.8
Week 2: Low disease activity (n=56)16.1
Week 24: Low disease activity (n=42)16.7
Week 52: Low disease activity (n=8)0
Baseline: Moderate disease activity (n=56)35.7
Week 2: Moderate disease activity (n=56)53.6
Week 24: Moderate disease activity (n=42)19.0
Week 52: Moderate disease activity (n=8)12.5
Baseline: High disease activity (n=56)62.5
Week 2: High disease activity (n=56)23.2
Week 24: High disease activity (n=42)0
Week 52: High disease activity (n=8)0
SecondaryPercentage of Participants Achieving a Clinically Significant Improvement in DAS28

The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Clinically Significant Improvement in DAS28
percentage of participantsTocilizumab
Week 2 (n=56)66.1
Week 24 (n=42)90.5
Week 52 (n=8)100
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity VAS

Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100= "maximum disease activity". This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Physician's Global Assessment of Disease Activity VAS
Units on a scaleTocilizumab
Baseline (n=56)64.93 ± 17.73
Change at Week 2 (n=56)-16.34 ± 16.88
Change at Week 24 (n=45)-48.93 ± 25.06
Change at Week 52 (n=9)-57.44 ± 23.26
SecondaryChange From Baseline in Patient's Global Assessment of Disease Activity VAS

PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100="maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Patient's Global Assessment of Disease Activity VAS
Units on a scaleTocilizumab
Baseline (n=57)67.28 ± 22.25
Change at Week 2 (n=57)-11.82 ± 23.23
Change at Week 24 (n=46)-36.02 ± 29.38
Change at Week 52 (n=9)-44.78 ± 35.87
SecondaryChange From Baseline in Patient's Assessment of Pain VAS

Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no pain" and the extreme right end 100="unbearable pain". A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2 and Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Patient's Assessment of Pain VAS
Units on a scaleTocilizumab
Baseline (n=57)66.77 ± 21.43
Change at Week 2 (n=57)-11.32 ± 19.74
Change at Week 24 (n=46)-35.37 ± 27.03
Change at Week 52 (n=9)-49.33 ± 39.58
SecondaryAcute Phase Reactants: Change From Baseline in CRP

A negative change from baseline in CRP level indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · milligrams per liter (mg/L)
Acute Phase Reactants: Change From Baseline in CRP
milligrams per liter (mg/L)Tocilizumab
Baseline (n=55)13.79 ± 20.78
Change at Week 2 (n=54)-13.19 ± 20.64
Change at Week 24 (n=42)-10.12 ± 14.50
Change at Week 52 (n=8)-25.07 ± 23.03
SecondaryAcute Phase Reactants: Change From Baseline in ESR

A negative change from baseline in ESR indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · millimeters per hour (mm/hr)
Acute Phase Reactants: Change From Baseline in ESR
millimeters per hour (mm/hr)Tocilizumab
Baseline (n=56)33.75 ± 28.90
Change at Week 2 (n=55)-19.95 ± 18.22
Change at Week 24 (n=44)-22.80 ± 24.88
Change at Week 52 (n=9)-27.78 ± 23.82
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
Units on a scaleTocilizumab
Baseline (n=57)1.44 ± 0.68
Change at Week 2 (n=57)-0.08 ± 0.43
Change at Week 24 (n=46)-0.54 ± 0.68
Change at Week 52 (n=9)-1.33 ± 0.68
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)

The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
Units on a scaleTocilizumab
Baseline (n=57)26.09 ± 10.75
Change at Week 2 (n=57)2.32 ± 9.58
Change at Week 24 (n=45)10.53 ± 12.06
Change at Week 52 (n=9)20.89 ± 12.35
SecondaryChange From Baseline in Pittsburgh Sleep Quality Index (PSQI)

The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 4, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)
Units on a scaleTocilizumab
Baseline (n=57)8.81 ± 4.39
Change at Week 4 (n=54)-1.24 ± 3.53
Change at Week 24 (n=46)-2.63 ± 4.14
Change at Week 52 (n=9)-4.56 ± 5.88
SecondaryChange From Baseline in Patient Quality of Sleep VAS

The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no difficulty to sleep" and the extreme right end 100="extreme sleeping difficulties". A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Quality of Sleep VAS
Units on a scaleTocilizumab
Baseline (n=57)54.95 ± 31.23
Change at Week 2 (n=57)-8.40 ± 23.72
Change at Week 24 (n=46)-21.93 ± 30.87
Change at Week 52 (n=9)-34.22 ± 37.03
SecondaryChange From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF)

The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 4, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF)
Units on a scaleTocilizumab
Baseline: Physical (n= 49)3.57 ± 1.92
Change at Week 4: Physical (n= 47)-0.57 ± 1.36
Change at Week 24: Physical (n=38)-1.41 ± 1.83
Change at Week 52: Physical (n=3)-3.62 ± 2.23
Baseline: Symptom (50)6.33 ± 2.59
Change at Week 4: Symptom (n= 48)-1.15 ± 2.46
Change at Week 24: Symptom (n=40)-2.69 ± 2.80
Change at Week 52: Symptom (n=3)-3.89 ± 5.91
Baseline: Affect (n=50)5.07 ± 2.22
Change at Week 4: Affect (n= 48)-0.66 ± 1.56
Change at Week 24: Affect (n=40)-1.74 ± 2.22
Change at Week 52: Affect (n=3)-4.50 ± 2.22
Baseline: Social (n=50)5.36 ± 1.73
Change at Week 4: Social (n= 48)0.18 ± 1.41
Change at Week 24: Social (n=40)-0.56 ± 1.61
Change at Week 52: Social (n=3)-1.46 ± 2.37
Baseline: Work (n=26)3.17 ± 2.46
Change at Week 4: Work (n= 23)-0.92 ± 2.53
Change at Week 24: Work (n=21)-0.65 ± 2.87
Change at Week 52: Work (n=1)3.75 ± NA
SecondaryChange From Baseline in Patient Fatigue VAS

The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no fatigue" and the extreme right end 100="extreme fatigue". A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Fatigue VAS
Units on a scaleTocilizumab
Baseline (n=57)60.19 ± 24.79
Change at Week 2 (n=57)-3.74 ± 20.68
Change at Week 24 (n=46)-21.48 ± 28.07
Change at Week 52 (n=9)-50.89 ± 26.11
SecondaryChange From Baseline in Patient Satisfaction VAS

The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no satisfaction" and the extreme right end 100="extremely satisfied". A positive change from baseline indicates an improvement.

Time frame:
From Baseline to Week 2, Week 24 and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Satisfaction VAS
Units on a scaleTocilizumab
Baseline (n=53)39.66 ± 28.63
Change at Week 2 (n=53)9.49 ± 33.97
Change at Week 24 (n=43)33.07 ± 35.50
Change at Week 52 (n=8)49.38 ± 35.12
SecondaryChange From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS)

The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low \< 10, moderate 10-17 and high \> 17. A negative change from baseline indicates an improvement.

Time frame:
From Baseline to Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS)
Units on a scaleTocilizumab
Baseline (n=26)13.15 ± 6.05
Change at Week 24 (n=22)-3.55 ± 6.96
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM ) Scores

The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction.

Time frame:
Week 24
Reported as:
Mean · Units on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores
Units on a scaleTocilizumab
Effectiveness (n=46)66.7 ± 19.07
Convenience (n=46)76.09 ± 15.66
Global Satisfaction (n=46)65.06 ± 15.52
SecondarySafety: Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Up to 52 weeks
Reported as:
Number · percentage of participants
Safety: Percentage of Participants With Adverse Events
percentage of participantsTocilizumab
Safety: Percentage of Participants With Adverse Events96.5
SecondarySafety: Percentage of Participants With Anti-tocilizumab Antibodies
Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Safety: Percentage of Participants With Anti-tocilizumab Antibodies
percentage of participantsTocilizumab
Baseline (n= 55)0
Week 24 (n= 43)1.7

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—5/57 (8.8%)36/57 (63.2%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
Atrial FlutterCardiac disorders1/57
Diverticular perforationGastrointestinal disorders1/57
HypersensitivityImmune system disorders1/57
Arthritis InfectiveInfections and infestations1/57
FallInjury, poisoning and procedural complications1/57
Femur FractureInjury, poisoning and procedural complications1/57
Chronic Lymphocytic LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/57
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTocilizumab
BronchitisInfections and infestations9/57
NasopharyngitisInfections and infestations7/57
CoughRespiratory, thoracic and mediastinal disorders7/57
Rheumatoid arthritisMusculoskeletal and connective tissue disorders5/57
HyperhidrosisSkin and subcutaneous tissue disorders5/57
VertigoEar and labyrinth disorders4/57
NauseaGastrointestinal disorders4/57
FatigueGeneral disorders4/57
Urinary tract infectionInfections and infestations4/57
Abdominal pain upperGastrointestinal disorders3/57

Baseline characteristics

The full analysis set (FAS) consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean54.49 ± 11.08
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female44
Male13
08

Study locations

17 sites
  • Aalst, 9300, Belgium
  • Assebroek, 8310, Belgium
  • Bonheiden, 2820, Belgium
  • Bruxelles, 1020, Belgium
  • Bruxelles, 1050, Belgium
  • Bruxelles, 1070, Belgium
  • Genk, 3600, Belgium
  • Gent, 9000, Belgium
  • Gilly (Charleroi), 6000, Belgium
  • Gosselies, 6041, Belgium
  • Haine-Saint-Paul, 7100, Belgium
  • Liège, 4000, Belgium
  • Roeselare, 8800, Belgium
  • Sijsele, 8340, Belgium
  • Sint-Niklaas, 9100, Belgium
  • Wilrijk, 2610, Belgium
  • Luxembourg, 2763, Luxembourg
09

References and documents

Publications

  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2013
First posted
Jan 9, 2014
Start
Jan 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Jan 4, 2017
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02031471
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 9, 2014
Start date
Jan 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Jan 4, 2017
Last update
Aug 1, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion